First Trust Advisors
ENTA icon

First Trust Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

First Trust Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-6,703
Closed -$307K – 2351
2020
Q3 		$307K Buy
6,703
+1,812
+37% +$87.8K ﹤0.01% 2156
2020
Q2 		$246K Buy
+4,891
New +$253K ﹤0.01% 2190
2019
Q4 		– Sell
-8,797
Closed -$529K – 2403
2019
Q3 		$529K Sell
8,797
-32,838
-79% -$2.44M ﹤0.01% 2098
2019
Q2 		$3.51M Buy
41,635
+16,401
+65% +$1.48M 0.01% 1257
2019
Q1 		$2.41M Buy
25,234
+2,681
+12% +$240K ﹤0.01% 1441
2018
Q4 		$1.6M Sell
22,553
-24,766
-52% -$1.9M ﹤0.01% 1601
2018
Q3 		$4.04M Sell
47,319
-21,957
-32% -$2.2M 0.01% 1261
2018
Q2 		$8.03M Buy
+69,276
New +$6.91M 0.02% 873
2016
Q2 		– Sell
-49,119
Closed -$1.44M – 2303
2016
Q1 		$1.44M Buy
49,119
+7,496
+18% +$209K ﹤0.01% 1474
2015
Q4 		$1.37M Buy
+41,623
New +$1.36M ﹤0.01% 1613

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

First Trust Advisors's ENTA Position: Q4 2020 in Review

First Trust Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q4 2020, closing a stake of 6,703 shares — an estimated $307K sold.

First Trust Advisors first reported a position in ENTA in Q4 2015 and held it in 10 quarters. The position peaked at $8.03M in Q2 2018. 151 funds tracked by Wall St. Rank hold ENTA as of Q4 2020.

  • First Trust Advisors reported no remaining Enanta Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • First Trust Advisors sold 6,703 Enanta Pharmaceuticals shares in Q4 2020, an estimated $307K.
  • First Trust Advisors first reported a position in Enanta Pharmaceuticals in Q4 2015 and held it in 10 quarters.
  • First Trust Advisors's Enanta Pharmaceuticals position peaked at $8.03M in Q2 2018.
  • 151 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2020.

Based on First Trust Advisors's 13F filing for Q4 2020, filed 2 Feb 2021.